Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2047-9158
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study ; volume:9 ; number:1 ; day:28 ; month:4 ; year:2020 ; pages:1-3 ; date:12.2020
Translational neurodegeneration ; 9, Heft 1 (28.4.2020), 1-3, 12.2020
- Creator
-
Reichmann, Heinz
Lees, Andrew
Rocha, José-Francisco
Magalhães, Diogo
Soares-da-Silva, Patrício
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40035-020-00193-3
- URN
-
urn:nbn:de:101:1-2020070821302031119704
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Reichmann, Heinz
- Lees, Andrew
- Rocha, José-Francisco
- Magalhães, Diogo
- Soares-da-Silva, Patrício
- SpringerLink (Online service)
Other Objects (12)
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Gender differences in non-motor fluctuations in Parkinson’s disease
Home monitoring of motor fluctuations in Parkinson’s disease patients
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Detecting motor symptom fluctuations in Parkinson’s disease with generative adversarial networks
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Gender differences in non-motor fluctuations in Parkinson’s disease
Home monitoring of motor fluctuations in Parkinson’s disease patients
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Detecting motor symptom fluctuations in Parkinson’s disease with generative adversarial networks
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study
Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial
Gender differences in non-motor fluctuations in Parkinson’s disease
Home monitoring of motor fluctuations in Parkinson’s disease patients
Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
Detecting motor symptom fluctuations in Parkinson’s disease with generative adversarial networks